Bionic pancreas decreases stress, improves treatment satisfaction in type 1 diabetes patients

Patients with type 1 diabetes experienced higher levels of treatment satisfaction and lower distress levels when using a bionic pancreas (BP), according to a study published by Mary Ann Liebert.

The bihormonal bionic pancreas assists type 1 diabetic patients in maintaining blood glucose levels by injecting insulin and glucagon, mimicking an actual pancreas. In this study, researchers enrolled 39 adults with type 1 diabetes to identify benefits of using BP compared to conventional care. Participants used the BP for 11 days followed by 11 days of conventional care. A psychosocial questionnaire was completed at baseline and at the end of the study.

Results showed that patients experienced improvements in psychosocial outcomes when using the BP over conventional care. Patients experienced reduced levels of diabetes-related distress related to hypoglycemia and eating constraints, improved treatment satisfaction and 69 percent of participants trusted the device. However, concerns about the burden of BP were also reported, with 75 percent of participants concerned about carrying around the BP, the need to change the glucagon daily and the wearability of the device.

“Overall, participants report substantial psychosocial benefits accruing from the BP relative to their usual method of diabetes care,” concluded first author J. Weissberg-Benchell and colleagues. “However, participants also reported a number of burdens associated with the system. Future versions of the BP device should be designed with the goal of addressing these concerns, and studies with larger, more diverse samples, and with more technology-naive participants are needed.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.